Taiho Oncology, Inc.
Phoenix, Arizona
What changed
Phase II trial registered: A Study of TAS-120 in Patients With Metastatic Breast Cancer
8mo agoTrial registeredNov 13, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 45 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase II
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Peer position
681 pre-ticker oncology companies at Phase II
Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.
Compare seatsA ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE2 registered
Jan 28, 2020Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification · TERMINATED · sponsor: Taiho Oncology, Inc. · A Study of TAS-120 in Patients With Metastatic Breast Cancer
ClinicalTrials.gov · NCT04024436 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources